Area of research
Nephrology · Genetics
Research interest
Research interests include Renal Diseases and Glomerulopathies, Chronic Kidney Disease and Diabetes, Genetic and Kidney Cyst Diseases, and Protease and Inhibitor Mechanisms.
Reduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mice with Diabetes.
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study.
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.
Remembering Eberhard Ritz: A Clinician-Scientist Extraordinaire.
Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study.
suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury.
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure.
The small GTPase regulatory protein Rac1 drives podocyte injury independent of cationic channel protein TRPC5.
Assay-related differences in SuPAR levels: implications for measurement and data interpretation.
SuPAR mediates viral response proteinuria by rapidly changing podocyte function.
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients.
Evaluation of a fast-and-frugal clinical decision algorithm ('pathways') on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants.
Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD.
Reply to: Apolipoprotein C3 induces inflammasome activation only in its delipidated form.
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
XOR risk variants drive diabetic kidney disease.
The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease.
Bone marrow from focal segmental glomerulosclerosis displays activation of inflammatory pathway
Changes in plasma soluble urokinase plasminogen activator receptor levels across pregnancy and in relation to hypertensive disorders.
Virus-response proteinuria underlies rapid changes in kidney filtration barrier function in COVID-19
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
Molecular consequences of SARS-CoV-2 liver tropism
Molecular consequences of SARS-CoV-2 liver tropism.
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.
Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound.
IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wounds.